Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | MMP1 | P03956 | 1/20 | 0.42 |
| ▸ | MMP2 | P08253 | 1/20 | 0.42 |
| ▸ | MMP3 | P08254 | 1/20 | 0.42 |
| ▸ | MMP7 | P09237 | 1/20 | 0.42 |
| ▸ | MMP9 | P14780 | 1/20 | 0.42 |
| ▸ | MMP13 | P45452 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 5/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | MME | P08473 | 1/20 | 0.32 |
| ▸ | ACE | P12821 | 1/20 | 0.32 |
| ▸ | CPA1 | P15085 | 1/20 | 0.32 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL697449 | 1.00 | ADAMTS4 (0.44) | ADAMTS4HTTMMP1MMP2MMP3 | |
| SCHEMBL18047580 | 1.00 | ADAMTS4 (0.44) | ADAMTS4HTTMMP1MMP2MMP3 | |
| Hydrochloric Acid SCHEMBL32662258 | 0.97 | ADAMTS4 (0.43) | ADAMTS4HTTMMP1MMP2MMP3 | |
| SCHEMBL725182 | 0.79 | ADAMTS4 (0.44) | ADAMTS4HTTMMP1MMP2MMP3 | |
| SCHEMBL5148621 | 0.79 | ADAMTS4 (0.44) | ADAMTS4HTTMMP1MMP2MMP3 | |
| SCHEMBL29633569 | 0.79 | ADAMTS4 (0.44) | ADAMTS4HTTMMP1MMP2MMP3 | |
| SCHEMBL8354666 | 0.79 | CA14 (0.39) | CA14CA2CA12 | |
| SCHEMBL15473444 | 0.79 | CA14 (0.39) | CA14CA2CA12 | |
| SCHEMBL5314799 | 0.77 | ADAMTS4 (0.43) | ADAMTS4HTTMMP1MMP2MMP3 | |
| SCHEMBL19485860 | 0.77 | CA14 (0.38) | CA14CA2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140080788-A1 | NOVEL BICYCLIC NITROGEN CONTAINING HETEROARYL TGR5 RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2014-03-20 | — | — | US | claimed |
| EP-0490667-B1 | HIV protease inhibitors | JAPAN ENERGY CORP (JP) | 1999-06-09 | — | — | EP | claimed |
| JP-58185516-A | — | — | None | — | — | JP | disclosed |
| US-20230011118-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED | 2023-01-12 | — | — | US | disclosed |
| WO-2021252859-A1 | INHIBITORS OF APOL1 AND USE OF THE SAME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-12-16 | — | — | WO | disclosed |
| EP-3154989-A1 | BETA-LACTAMASE INHIBITORS | Venatorx Pharmaceuticals, Inc. (US) | 2017-04-19 | — | — | EP | disclosed |
| EP-3105225-A1 | NOVEL 3-(INDOL-3-YL)-PYRIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | iTeos Therapeutics (BE) | 2016-12-21 | — | — | EP | disclosed |
| WO-2015191907-A1 | BETA-LACTAMASE INHIBITORS | VenatoRx Pharmaceuticals, Inc. (US) | 2015-12-17 | — | — | WO | disclosed |
| WO-2015121812-A1 | NOVEL 3-(INDOL-3-YL)-PYRIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | ITEOS THERAPEUTICS (BE) | 2015-08-20 | — | — | WO | disclosed |
| EP-2423211-B1 | PROCESSES FOR PRODUCING (1S,6S)- OR (1R,6R)-CIS-2,8-DIAZABICYCLO[4.3.0]NONANE AND INTERMEDIATE THEREOF | KANEKA CORP (JP) | 2014-04-16 | — | — | EP | disclosed |
| EP-2423211-A1 | PROCESSES FOR PRODUCING (1S,6S)- OR (1R,6R)-CIS-2,8-DIAZABICYCLO[4.3.0]NONANE AND INTERMEDIATE THEREOF | Kaneka Corporation (JP) | 2012-02-29 | — | — | EP | disclosed |
| WO-2005016387-A2 | DNA-DEPENDENT MRI CONTRAST AGENTS | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2005-02-24 | — | — | WO | disclosed |
| WO-2003066624-A1 | PYRIMIDINONESULFAMOYLUREAS AS INTEGRIN LIGANDS | ABBOTT GMBH & CO. KG (DE) | 2003-08-14 | — | — | WO | disclosed |
| EP-1027328-A1 | SUBSTITUTED ANILIDES | Aventis Pharma Limited (GB) | 2000-08-16 | — | — | EP | disclosed |
| EP-0490667-B1 | HIV protease inhibitors | JAPAN ENERGY CORP (JP) | 1999-06-09 | — | — | EP | disclosed |
| WO-1999023063-A1 | SUBSTITUTED ANILIDES | AVENTIS PHARMA LIMITED (GB) | 1999-05-14 | — | — | WO | disclosed |
| EP-0574135-B1 | Process for producing peptide derivatives and salts thereof | JAPAN ENERGY CORP (JP) | 1998-11-18 | — | — | EP | disclosed |
| US-5644028-A | Process for producing peptide derivatives and salts therefor | JAPAN ENERGY CORPORATION (JP) | 1997-07-01 | — | — | US | disclosed |
| EP-0574135-A1 | Process for producing peptide derivatives and salts thereof | JAPAN ENERGY CORPORATION (JP) | 1993-12-15 | — | — | EP | disclosed |
| JP-S58185516-A | TAPE DRUG | NITTO ELECTRIC IND CO LTD | 1983-10-29 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230011118-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | APOL1, APOB, SAAL1 | ADAMTS4 2574/4885HTT 2086/4885MMP1 1144/4885 |
| US-20140080788-A1 | NOVEL BICYCLIC NITROGEN CONTAINING HETEROARYL TGR5 RECEPTOR MODULATORS | GRK5, GPBAR1, GPR55 | ADAMTS4 4357/4885HTT 1262/4885MMP1 4779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.